RxSight Sees Q2 Sales $32.000M-$34.000M vs $32.077M Est

Benzinga Newsdesk www.benzinga.com Positive 81.7%

Neg 0% Neu 0% Pos 81.7%

RxSight (NASDAQ:RXST) sees Q2 sales of $32.000 million-$34.000 million vs $32.077 million analyst estimate.

Comments

No comments yet. Be the first!